A systematic review and critical assessment of health state utilities: weight change and type 2 diabetes mellitus.

abstract：BACKGROUND:Like other developed countries with aging populations, Sweden is expecting large increases in the prevalence of Alzheimer's disease and corresponding escalations in the cost of care for patients with this disease. Galantamine, a new acetylcholinesterase inhibitor and nicotinic modulator, has proved effective...

journal_title：PharmacoEconomics

authors： Garfield FB,Getsios D,Caro JJ,Wimo A,Winblad B

更新日期：2002-01-01 00:00:00

abstract：:Using the method of willingness to pay (WTP), this study assesses the value of a new antidepressant, moclobemide, relative to that of tricyclic antidepressants (TCAs), which have equivalent efficacy but less favourable adverse effect profiles. From a published meta-analysis of controlled clinical trials, we identified...

journal_title：PharmacoEconomics

authors： O'Brien BJ,Novosel S,Torrance G,Streiner D

更新日期：1995-07-01 00:00:00

abstract：:Cost-effectiveness analysis (CEA) is one of the main tools of economic evaluation. Every CEA is based on a number of assumptions, some of which may not be accurate, introducing uncertainty. Sensitivity analysis (SA) formalizes ways to measure and evaluate this uncertainty. Specific sources of uncertainty in CEA have b...

journal_title：PharmacoEconomics

authors： Jain R,Grabner M,Onukwugha E

更新日期：2011-04-01 00:00:00

abstract：:There are insufficient resources in the UK to fund all new technologies and new indications approved by the National Institute for Health and Clinical Excellence (NICE). Diverting funding from existing sources will have a detrimental effect on the provision of other priority services. The UK Office of Fair Trading (OF...

journal_title：PharmacoEconomics

authors： Godman B,Haycox A,Schwabe U,Joppi R,Garattini S

更新日期：2008-01-01 00:00:00

abstract：INTRODUCTION:The objective of this study was to evaluate the potential economic implications of using etoricoxib versus non-selective NSAID alternatives in the treatment of patients with osteoarthritis (OA) or rheumatoid arthritis (RA) in the UK. STUDY DESIGN:Decision-analytical modelling was used to calculate the exp...

journal_title：PharmacoEconomics

authors： Moore A,Phillips C,Hunsche E,Pellissier J,Crespi S

更新日期：2004-01-01 00:00:00

abstract：:Over the last decade, there has been a proliferation in the number of economic evaluations of pharmaceuticals to meet the growing demand for information about the economic benefits of healthcare technologies. The majority of these studies have been commissioned by pharmaceutical companies for the purposes of drawing a...

journal_title：PharmacoEconomics

authors： Pang F

更新日期：2002-01-01 00:00:00

abstract：:Advanced controlled release (CR) dosage forms are relative newcomers to pharmaceutical markets, and few studies relate their efficacy, safety or compliance benefits to economic value. This literature review was undertaken to assess the cost effectiveness of CR dosage forms using such measures as purchase costs, total ...

journal_title：PharmacoEconomics

authors： Cramer MP,Saks SR

更新日期：1994-06-01 00:00:00

abstract：BACKGROUND:Heart failure (HF) is a well-recognized public health concern and imposes high economic and societal costs. Decision analytic models exist for evaluating the economic ramifications associated with HF. Despite this, studies that appraise these modelling approaches for augmenting best-practice decisions remain...

journal_title：PharmacoEconomics

authors： Di Tanna GL,Bychenkova A,O'Neill F,Wirtz HS,Miller P,Ó Hartaigh B,Globe G

更新日期：2019-03-01 00:00:00

abstract：:Economic analysts are increasingly likely to rely on systematic reviews and meta-analyses of health state utility values to inform the parameter inputs of decision-analytic modelling-based economic evaluations. Beyond the context of economic evaluation, evidence from systematic reviews and meta-analyses of health stat...

journal_title：PharmacoEconomics

authors： Petrou S,Kwon J,Madan J

更新日期：2018-09-01 00:00:00

abstract：BACKGROUND:Schizophrenia is a devastating and costly illness that affects 1% of the population in the US. Effective pharmacological therapies are available but suboptimal patient adherence to either acute or long-term therapeutic regimens reduces their effectiveness. The availability of a long-acting injection (LAI) fo...

journal_title：PharmacoEconomics

authors： Edwards NC,Rupnow MF,Pashos CL,Botteman MF,Diamond RJ

更新日期：2005-01-01 00:00:00

abstract：:Total hip arthroplasty (THA) is a major orthopaedic procedure with a high risk of postoperative thromboembolism. Increasing demand for this type of surgery, together with its high cost, has led to examination of means by which the cost of THA may be minimised. Current clinical opinion favours the use of suitable pharm...

journal_title：PharmacoEconomics

authors： Dunn CJ,Goa KL

更新日期：1996-08-01 00:00:00

abstract：:Variable compliance with prescribed drug regimens is a leading source of variability in drug response. Specifics differ by drug and disease. The role of variable compliance was clearly defined in 2 trials of lipid-lowering agents, cholestyramine and gemfibrozil, in which exceptionally careful measurements of complianc...

journal_title：PharmacoEconomics

authors： Urquhart J

更新日期：1999-03-01 00:00:00

abstract：:There is growing interest in using observational data to assess the safety, effectiveness, and cost effectiveness of medical technologies, but operational, technical, and methodological challenges limit its more widespread use. Common data models and federated data networks offer a potential solution to many of these ...

journal_title：PharmacoEconomics

authors： Kent S,Burn E,Dawoud D,Jonsson P,Østby JT,Hughes N,Rijnbeek P,Bouvy JC

更新日期：2020-12-18 00:00:00

abstract：:Productivity costs are frequently omitted from economic evaluations, despite their often strong impact on cost-effectiveness outcomes. This neglect may be partly explained by the lack of standardization regarding the methodology of estimating productivity costs. This paper aims to contribute to standardization of prod...

journal_title：PharmacoEconomics

authors： Krol M,Brouwer W

更新日期：2014-04-01 00:00:00

abstract：:Uncertainty in the decision-making process for reimbursement of health technologies could be reduced if additional information were available. Although methods to evaluate the monetary value of the uncertainty have been previously described, an economic evaluation of alternative methods to acquire additional informati...

journal_title：PharmacoEconomics

authors： Shavit O,Leshno M,Goldberger A,Shmueli A,Hoffman A

更新日期：2007-01-01 00:00:00

abstract：UNLABELLED:Cyclosporin microemulsion (Neoral) is a self-emulsifying preconcentrate of cyclosporin which is more rapidly and consistently absorbed than the original oil-based formulation of cyclosporin (standard formulation; Sandimmun, Sandimmune). This superior pharmacokinetic profile suggests that cyclosporin microemu...

journal_title：PharmacoEconomics

authors： Coukell AJ,Plosker GL

更新日期：1998-12-01 00:00:00

abstract：:Cost-utility analysis (CUA) is a technique that can potentially be used as a guide to allocating healthcare resources so as to obtain the maximum health benefits possible under a given budget constraint. However, it is not clear that current practice captures societal preferences regarding health benefits. In analyses...

journal_title：PharmacoEconomics

authors： Cohen BJ

更新日期：2003-01-01 00:00:00

abstract：:There is an inevitable tension between robust reimbursement processes and providing speedy access to new and novel technologies, given uncertainties about key pieces of evidence and subsequent concerns regarding their overall efficiency. The public perception of these treatments as 'breakthrough', combined with substa...

journal_title：PharmacoEconomics

authors： McCabe CJ,Stafinski T,Edlin R,Menon D,Banff AED Summit.

更新日期：2010-01-01 00:00:00

abstract：:The pharmacoeconomics of the low molecular weight heparin (LMWH) enoxaparin in the prophylaxis and treatment of venous thromboembolism have mostly been investigated in cost-effectiveness studies that estimated direct costs associated with treatment, using decision analyses and clinical outcome data from randomised con...

journal_title：PharmacoEconomics

authors： Bergqvist D

更新日期：2002-01-01 00:00:00

abstract：:Total hip and knee replacements (THR and TKR) are high-risk settings for venous thromboembolism (VTE). This review summarizes the cost effectiveness of VTE prophylaxis regimens for THR and TKR. We searched MEDLINE (January 1997 to October 2009), EMBASE (January 1997 to June 2009) and the UK NHS Economic Evaluation Dat...

journal_title：PharmacoEconomics

authors： Kapoor A,Chuang W,Radhakrishnan N,Smith KJ,Berlowitz D,Segal JB,Katz JN,Losina E

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:Over 200 million people have chronic obstructive pulmonary disease (COPD) worldwide. The number of disease-year equivalents and deaths attributable to COPD are high. Guidelines for the pharmacological treatment of the disease recommend an individualized step-up approach in which treatment is intensified when...

journal_title：PharmacoEconomics

authors： Rutten-van Mölken MP,Goossens LM

更新日期：2012-04-01 00:00:00

abstract：:As part of the Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (AstraZeneca) of durvalumab (IMFINZITM) to submit evidence for the clinical and cost effectiveness of durvalumab for the treatment of patients with locally advanced, unresecta...

journal_title：PharmacoEconomics

authors： Witlox WJA,van Asselt ADI,Wolff R,Armstrong N,Worthy G,Chalker A,Buksnys T,Stirk L,Kleijnen J,Joore MA,Grimm SE

更新日期：2020-04-01 00:00:00

abstract：OBJECTIVE:To estimate the potential savings in overall cardiovascular disease (CVD) treatment costs for the US population with coronary artery disease (CAD) resulting from the use of amlodipine. STUDY DESIGN AND METHODS:Using patient-level data from a retrospective analysis of the Prospective Evaluation of the Vascula...

journal_title：PharmacoEconomics

authors： Casciano R,Doyle JJ,Chen J,Arikian S,Casciano J,Kugel H,Arocho R

更新日期：2002-01-01 00:00:00

abstract：OBJECTIVES:To obtain utility estimates suitable for use in economic models for chronic spontaneous (idiopathic) urticaria (CSU). METHODS:Patient-level data from three randomized clinical trials-ASTERIA I, ASTERIA II and GLACIAL-were analysed. Health states were derived from the Urticaria Activity Score over 7 days (UA...

journal_title：PharmacoEconomics

authors： Hawe E,McBride D,Balp MM,Tian H,Halliday A,Stull DE

更新日期：2016-05-01 00:00:00

abstract：:Health economic evaluation is a framework for the comparative analysis of the incremental health gains and costs associated with competing decision alternatives. The process of developing health economic models is usually complex, financially expensive and time-consuming. For these reasons, model development is someti...

journal_title：PharmacoEconomics

authors： Bermejo I,Tappenden P,Youn JH

更新日期：2017-11-01 00:00:00

abstract：OBJECTIVE:Pertussis is a highly contagious infection affecting mainly children. Acellular pertussis vaccines were recently introduced in Canada based on evidence of improved safety and efficacy over whole cell vaccines, the current standard of care. The following study reports the economic impact of replacing the whole...

journal_title：PharmacoEconomics

authors： Iskedjian M,Einarson TR,O'Brien BJ,De Serres JG,Gold R,Gemmill IM,Milkovich N,Rosner A

更新日期：2001-01-01 00:00:00

abstract：:The annual cost of managing migraine totals billions of US dollars. This retrospective economic analysis of a clinical trial comparing subcutaneous dihydroergotamine mesylate (DHE) with subcutaneous sumatriptan in the treatment of acute migraine is appropriate because, although each product has been shown to be effica...

journal_title：PharmacoEconomics

authors： Payne K,Kozma CM,Lawrence BJ

更新日期：1996-07-01 00:00:00

abstract：:A variety of problems are associated with the operation, quality, costs, and benefits of therapeutic substitution programmes. Adequate communication of procedures, events, and failures are essential features of a safe therapeutic substitution policy. However, case reports of suboptimal therapy and differences in pha...

journal_title：PharmacoEconomics

authors： Levy RA

更新日期：1992-01-01 00:00:00

abstract：:A growing body of recent work has identified several problems with economic evaluations undertaken alongside controlled trials that can have potentially serious impacts on the ability of decision makers to draw valid conclusions. At the same time, the use of cost-effectiveness models has been drawn into question, due ...

journal_title：PharmacoEconomics

authors： McCabe C,Dixon S

更新日期：2000-05-01 00:00:00

abstract：:There is a global perspective to the economic consequences of diabetes, which is illustrated in the many publications now being produced on this subject. Because of the higher prevalence of type II diabetes, its impact is greater than that of type I diabetes in both developed and developing countries (but particularly...

journal_title：PharmacoEconomics

authors： Williams R

更新日期：1995-01-01 00:00:00